| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T122 |
0-92 |
Sentence |
denotes |
Ribavirin is currently being evaluated in few trials for the treatment of COVID-19 patients. |
| T123 |
93-278 |
Sentence |
denotes |
It is being tested alone (NCT04356677; n = 50) or in combination with nitazoxanide and ivermectin (NCT04392427; n = 100) or with lopinavir/ritonavir and INF β-1b (NCT04276688; n = 127). |
| T124 |
279-382 |
Sentence |
denotes |
Recent computational work has shown that ribavirin binds with high affinity to RdRp of SARS-CoV-2 [55]. |
| T125 |
383-489 |
Sentence |
denotes |
Furthermore, the MERS-CoV rhesus macaque model revealed promising results for ribavirin and IFN-α 2b [56]. |
| T126 |
490-626 |
Sentence |
denotes |
Nevertheless, mixed results came out of treating MERS-CoV infections with a combination of ribavirin and IFNs (IFN-β1 or IFN-α 2a) [57]. |
| T127 |
627-848 |
Sentence |
denotes |
Results from the in vitro testing of ribavirin in Vero E6 cells also indicated that the replication and/or the cellular spread of SARS-CoV was not inhibited at concentrations known to inhibit other sensitive viruses [58]. |
| T128 |
849-1231 |
Sentence |
denotes |
Interestingly, a recent open-label randomized controlled trial (NCT04276688; n = 127) indicated that early triple antiviral therapy of INF-β 1b, ribavirin, and lopinavir/ritonavir was safe and superior to lopinavir/ritonavir alone in alleviating the symptoms and shortening the duration of viral shedding and hospitalization in COVID-19 patients with mild to moderate symptoms [59]. |
